| The effect of nitric oxide synthase inhibitor on improved insulin action by pioglitazone in high-fructose-fed rats. | |
| | |
MedLine Citation:
|
PMID: 14681837 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The present study was performed to investigate whether nitric oxide synthase (NOS) inhibition influences the increased whole-body insulin action by pioglitazone in high-fructose-fed rats. Male Wistar rats aged 6 weeks were randomly divided into 3 groups and each group was fed one of the following diets for 3 weeks: standard chow diet (control group), high-fructose diet (fructose-fed group), and high-fructose diet plus pioglitazone (pioglitazone-treated group). The control and pioglitazone-treated groups were further divided into 2 subgroups respectively, and some rats of each subgroup were infused the NOS inhibitor, N(G)-monomethyl-l-arginine (L-NMMA), during the euglycemic clamp studies. In vivo insulin action was determined by the 2-step (3 and 30 mU/kg body weight [BW]/min low- and high-dose, respectively) hyperinsulinemic euglycemic clamp procedure in the awake condition. Glucose infusion rate (GIR) was considered as the index of insulin action. Endothelium-type NOS (eNOS) and inducible NOS (iNOS) in skeletal muscle were also measured. At the low-dose clamp, high-fructose feeding produced a marked decrease in GIR compared with the control group. Pioglitazone-treated animals showed a significant increase in GIR, reaching a similar level as the control group. However, the improved GIR was decreased to the level of the fructose-fed group by L-NMMA infusion. The GIR of the control group was not affected by L-NMMA infusion. The same tendency as the low-dose clamp was found at the high-dose clamp. In skeletal muscle, eNOS and iNOS protein content were not affected by high-fructose feeding and/or pioglitazone treatment. These results suggest that NOS inhibition can decrease the improved insulin resistance by pioglitazone in high-fructose-fed rats. Therefore, although NOS protein content is not changed by high-fructose feeding and/or pioglitazone treatment, it could be concluded that nitric oxide (NO) plays an important role in the improvement of insulin action by pioglitazone. |
| | |
Authors:
|
K Koshinaka; Y Oshida; Y-Q Han; I Ohsawa; Y Sato |
Related Documents
:
|
8410367 - Carbohydrate utilization by tilapia (oreochromis niloticus x o. aureus) as influenced b... 10877197 - Ad libitum intake of low-fat diets rich in either starchy foods or sucrose: effects on ... 11179857 - Green, oolong and black tea extracts modulate lipid metabolism in hyperlipidemia rats f... 12122467 - Different functions of two alarm substances in the honeybee. 17009757 - Nest ornamentation by female spotless starlings in response to a male display: an exper... 6674877 - The susceptibility of renal arterial forks in rabbits to dietary-induced lipid deposition. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Metabolism: clinical and experimental Volume: 53 ISSN: 0026-0495 ISO Abbreviation: Metab. Clin. Exp. Publication Date: 2004 Jan |
Date Detail:
|
Created Date: 2003-12-18 Completed Date: 2004-02-18 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0375267 Medline TA: Metabolism Country: United States |
Other Details:
|
Languages: eng Pagination: 22-7 Citation Subset: IM |
Affiliation:
|
Department of Sports Medicine, Graduate School of Medicine and the Research Center of Health, Physical Fitness and Sports, Nagoya University, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Body Weight Dietary Carbohydrates / administration & dosage Eating Enzyme Inhibitors / pharmacology* Fructose / administration & dosage Glucose / administration & dosage, metabolism Glucose Clamp Technique Hypoglycemic Agents / pharmacology* Insulin / pharmacology* Male Muscle, Skeletal / enzymology Nitric Oxide / physiology Nitric Oxide Synthase / analysis, antagonists & inhibitors* Nitric Oxide Synthase Type II Nitric Oxide Synthase Type III Rats Rats, Wistar Thiazolidinediones / pharmacology* omega-N-Methylarginine / pharmacology |
| Chemical | |
Reg. No./Substance:
|
0/Dietary Carbohydrates; 0/Enzyme Inhibitors; 0/Hypoglycemic Agents; 0/Thiazolidinediones; 10102-43-9/Nitric Oxide; 11061-68-0/Insulin; 111025-46-8/pioglitazone; 17035-90-4/omega-N-Methylarginine; 30237-26-4/Fructose; 50-99-7/Glucose; EC 1.14.13.39/Nitric Oxide Synthase; EC 1.14.13.39/Nitric Oxide Synthase Type II; EC 1.14.13.39/Nitric Oxide Synthase Type III; EC 1.14.13.39/Nos2 protein, rat; EC 1.14.13.39/Nos3 protein, rat |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Leukocyte ABCA1 gene expression is associated with fasting glucose concentration in normoglycemic me...
Next Document: Effects of food restriction on peroxisome proliferator-activated receptor-gamma and glucocorticoid r...